MARKET

URGN

URGN

Urogen Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.31
+0.01
+0.05%
After Hours: 19.31 0 0.00% 16:41 09/25 EDT
OPEN
19.14
PREV CLOSE
19.30
HIGH
19.83
LOW
19.08
VOLUME
101.01K
TURNOVER
--
52 WEEK HIGH
35.21
52 WEEK LOW
13.12
MARKET CAP
425.28M
P/E (TTM)
-3.1412
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Oppenheimer: 3 Stocks That Could Surge Over 100% From Current Levels
So far, September has been a wild ride of ups and downs. Following the recent bout of volatility, stocks have ticked higher again. But as uncertainty regarding another rescue program and the presidential election continues to linger, where does the market go from here? Weighing in for Oppenheimer, Chief
TipRanks · 09/15 17:14
UroGen Pharma Announces September 2020 Conference Schedule
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will present at the following virtual conferences in September:
Business Wire · 09/10 12:00
UroGen Pharma Expands Executive Team to Accelerate Platform Innovation and Drive Commercial Growth
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the appointment of three new executives to the Company's Executive Leadership Team (ELT). These new hires, all
Business Wire · 09/09 12:00
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units ("RSUs") to nineteen new employees
Business Wire · 09/04 12:00
BeiGene COVID-19 Deal And Other News: The Good, Bad And Ugly Of Biopharma
BeiGene signs deal with Singlomics for neutralizing COVID-19 antibodies.UroGen flunks Phase 2 RTGel combo study.Matinas BioPharma reports progress for ENHANCE-IT study.
Seekingalpha · 08/30 08:22
UroGen's Phase 2 RTGel combo study for OAB misses primary endpoint
UroGen (URGN) -3.8% in premarket, says Phase 2 trial of RTGel hydrogel formulation in combination with Botox did not meet the primary endpoint of improvement of overactive bladder ((OAB)) symptoms, as measured
Seekingalpha · 08/27 12:59
UroGen Pharma Announces Update On Phase 2 Trial Of RTGel Hydrogel Formulation In Combination With BOTOX Intravesical Instillation For Overactive Bladder, Urinary Incontinence; Trial Did Not Meet Primary Endpoint
UroGen Pharma Announces Update on the Phase 2 Trial of an RTGel™ Hydrogel Formulation in Combination with BOTOX® (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary
Benzinga · 08/27 12:22
Oncology Stocks Area Trading Materially Lower The Last 2 Months
Seeking Alpha - Article · 08/24 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of URGN. Analyze the recent business situations of Urogen Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average URGN stock price target is 44.14 with a high estimate of 59.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 115
Institutional Holdings: 18.27M
% Owned: 82.97%
Shares Outstanding: 22.02M
TypeInstitutionsShares
Increased
39
1.93M
New
20
-1.09M
Decreased
16
208.84K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.00%
Pharmaceuticals & Medical Research
+1.53%
Key Executives
Chairman/Independent Director
Arie Belldegrun
President/Chief Executive Officer/Director
Elizabeth Barrett
Chief Financial Officer
Peter Pfreundschuh
Executive Vice President
Marina Konorty
Executive Vice President
Jim Ottinger
Chief Compliance Officer/General Counsel
Jason Smith
Other
Jeff Bova
Other
Polly Murphy
Other
Mark Schoenberg
Other
Elyse Seltzer
Independent Director
Cynthia Butitta
Independent Director
Fred Cohen
Independent Director
Kathryn Falberg
Independent Director
Stuart Holden
Independent Director
Ran Nussbaum
Independent Director
Shawn Tomasello
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About URGN
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Urogen Pharma Ltd stock information, including NASDAQ:URGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, URGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading URGN stock methods without spending real money on the virtual paper trading platform.